Israel-based Kamada Ltd announced this week that it has entered into an agreement with Iceland-based Alvotech to commercialize 6 biosimilar products in Israel once the products gain local regulatory approval.
Israel-based Kamada Ltd announced this week that it has entered into an agreement with Iceland-based Alvotech to commercialize 6 biosimilar products in Israel once the products gain local regulatory approval.
Among the products that will be sold by Kamada is PF708, a teriparatide biosimilar that was also recently approved in the United States—as a follow-on product—and that is licensed to Pfenex. Alvotech’s sister company, Alvogen, will be Pfenex’s US commercialization partner, per an October announcement from the drug makers.
In the Israeli market, an additional 5 undisclosed products are expected to be launched between 2023 and 2025.
The current market for the reference products of the 6 biosimilars covered by the agreement is estimated to be $125 million to $150 million per year in Israel, and based on anticipated market penetration and price competition after biosimilar introduction, Kamada estimates that it will be able to achieve sales of $20 million to $30 million per year.
“Our partnership with Alvotech will leverage our existing commercial infrastructure in Israel and enable Kamada to benefit from the long-term growth potential of the emerging class of biosimilar drugs,” said Amir London, chief executive officer (CEO) of Kamada, in a statement announcing the deal.
Mark Levick, CEO of Alvotech, added, “We are delighted to establish this important partnership with Kamada, who is an ideal commercial partner in Israel. Together, we will provide patients with better access to high-quality and cost-effective biosimilar medicines.”
This latest deal follows shortly after Alvotech formed several additional partnerships; in November, the drug maker announced that it has entered into an exclusive partnership with Germany-based Stada to commercialize 7 biosimilars—including autoimmune, oncology, ophthalmology, and inflammatory disease therapies—in Europe. In September, it announced a contract manufacturing partnership with Singapore’s Prestige Biopharma. Finally, in April, it announced a deal with Fuji Pharma to sell a biosimilar ustekinumab in Japan.
Challenges, Obstacles, and Future Directions for Anti-TNF Biosimilars in IBD
November 9th 2024A review article on tumor necrosis factor (TNF)-α inhibitors in inflammatory bowel disease (IBD) outlined current use of anti-TNF originators and biosimilars, their efficacy and safety, the benefits and challenges of biosimilars, and the future of biosimilars in IBD.
Biosimilars in America: Overcoming Barriers and Maximizing Impact
July 21st 2024Join us as we explore the complexities of the US biosimilars market, discussing legislative influences, payer and provider adoption factors, and strategies to overcome industry challenges with expert insights from Kyle Noonan, PharmD, MS, value & access strategy manager at Cencora.
Eye on Pharma: Henlius, Organon Updates; Meitheal Portfolio Expansion; Celltrion Zymfentra Data
November 5th 2024Henlius and Organon’s pertuzumab biosimilar met phase 3 goals; Meitheal expanded its US biosimilars; Celltrion’s subcutaneous infliximab (Zymfentra) showed monotherapy could be as effective as combination therapy for inflammatory bowel disease.
Exploring the Biosimilar Horizon: Julie Reed's Predictions for 2024
February 18th 2024On this episode of Not So Different, Julie Reed, executive director of the Biosimilars Forum, returns to discuss her predictions for the biosimilar industry for 2024 and beyond as well as the impact that the Forum's 4 new members will have on the organization's mission.
Panelists Stress Stakeholder Education to Build Confidence in Biosimilars
October 31st 2024By expanding educational initiatives to clarify biosimilar safety, efficacy, and interchangeability, stakeholders can foster trust, improve access, and ensure that biosimilars are widely accepted as high-quality, cost-effective alternatives to originator biologics.
Enhancing Adoption of Infused Biosimilars for a Sustainable Future
October 30th 2024An IQVIA report highlights challenges to the sustainability of infused biosimilars in the US, citing rebate walls and reimbursement policies, and proposes key solutions to enhance adoption and benefits for all stakeholders.